Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 111

1.

Rationalization of the Membrane Permeability Differences in a Series of Analogue Cyclic Decapeptides.

Witek J, Wang S, Schroeder B, Lingwood R, Dounas A, Roth HJ, Fouché M, Blatter M, Lemke O, Keller B, Riniker S.

J Chem Inf Model. 2019 Jan 28;59(1):294-308. doi: 10.1021/acs.jcim.8b00485. Epub 2018 Dec 4.

PMID:
30457855
2.

Treatment with HC-070, a potent inhibitor of TRPC4 and TRPC5, leads to anxiolytic and antidepressant effects in mice.

Just S, Chenard BL, Ceci A, Strassmaier T, Chong JA, Blair NT, Gallaschun RJ, Del Camino D, Cantin S, D'Amours M, Eickmeier C, Fanger CM, Hecker C, Hessler DP, Hengerer B, Kroker KS, Malekiani S, Mihalek R, McLaughlin J, Rast G, Witek J, Sauer A, Pryce CR, Moran MM.

PLoS One. 2018 Jan 31;13(1):e0191225. doi: 10.1371/journal.pone.0191225. eCollection 2018.

3.

Interconversion Rates between Conformational States as Rationale for the Membrane Permeability of Cyclosporines.

Witek J, Mühlbauer M, Keller BG, Blatter M, Meissner A, Wagner T, Riniker S.

Chemphyschem. 2017 Dec 6;18(23):3309-3314. doi: 10.1002/cphc.201700995. Epub 2017 Nov 2.

PMID:
28921848
4.

Correction to Kinetic Models of Cyclosporin A in Polar and Apolar Environments Reveal Multiple Congruent Conformational States.

Witek J, Keller BG, Blatter M, Meissner A, Wagner T, Riniker S.

J Chem Inf Model. 2017 Sep 25;57(9):2393. doi: 10.1021/acs.jcim.7b00502. Epub 2017 Sep 12. No abstract available.

PMID:
28898064
5.

Cross-Linked Collagen Triple Helices by Oxime Ligation.

Hentzen NB, Smeenk LEJ, Witek J, Riniker S, Wennemers H.

J Am Chem Soc. 2017 Sep 13;139(36):12815-12820. doi: 10.1021/jacs.7b07498. Epub 2017 Sep 5.

PMID:
28872857
6.

Neutralization of cement-asbestos waste by melting in an arc-resistance furnace.

Witek J, Kusiorowski R.

Waste Manag. 2017 Nov;69:336-345. doi: 10.1016/j.wasman.2017.08.017. Epub 2017 Aug 12.

PMID:
28811147
7.

Clinical and virological predictors of sustained response with an interferon-based simeprevir regimen for patients with chronic genotype 1 hepatitis C virus infection.

D'Offizi G, Cammà C, Taibi C, Schlag M, Weber K, Palma M, DeMasi R, Janssen K, Witek J, Lionetti R.

New Microbiol. 2017 Jan;40(1):19-26. Epub 2017 Jan 9.

8.

Virology analyses of HCV genotype 4 isolates from patients treated with simeprevir and peginterferon/ribavirin in the Phase III RESTORE study.

Fevery B, Verbinnen T, Peeters M, Janssen K, Witek J, Jessner W, De Meyer S, Lenz O.

J Viral Hepat. 2017 Jan;24(1):28-36. doi: 10.1111/jvh.12614. Epub 2016 Oct 3.

PMID:
27696653
9.

Kinetic Models of Cyclosporin A in Polar and Apolar Environments Reveal Multiple Congruent Conformational States.

Witek J, Keller BG, Blatter M, Meissner A, Wagner T, Riniker S.

J Chem Inf Model. 2016 Aug 22;56(8):1547-62. doi: 10.1021/acs.jcim.6b00251. Epub 2016 Jul 19. Erratum in: J Chem Inf Model. 2017 Sep 25;57(9):2393.

PMID:
27387150
10.

Efficacy of telaprevir-based therapy in stable liver transplant patients with chronic genotype 1 hepatitis C.

Forns X, Didier S, Mutimer D, Fagiuoli S, Navasa M, Agarwal K, Berenguer M, Colombo M, Herzer K, Nevens F, Daems B, Janssen K, Ouwerkerk-Mahadevan S, Kimko H, Lathouwers E, Witek J, Van Solingen-Ristea R.

Ann Hepatol. 2016 Jul-Aug;15(4):512-23.

11.

Pre-existence and Persistence of Resistant Minority Hepatitis C Virus Variants in Genotype 1-Infected Patients Treated With Simeprevir/Peginterferon/Ribavirin.

Fevery B, Thys K, Van Eygen V, Verbinnen T, Van Rossem E, Buelens A, Aerssens J, Witek J, Picchio G, De Meyer S, Lenz O.

Open Forum Infect Dis. 2016 Mar 14;3(2):ofw052. doi: 10.1093/ofid/ofw052. eCollection 2016 Mar.

12.

Rational design in search for 5-phenylhydantoin selective 5-HT7R antagonists. Molecular modeling, synthesis and biological evaluation.

Kucwaj-Brysz K, Warszycki D, Podlewska S, Witek J, Witek K, González Izquierdo A, Satała G, Loza MI, Lubelska A, Latacz G, Bojarski AJ, Castro M, Kieć-Kononowicz K, Handzlik J.

Eur J Med Chem. 2016 Apr 13;112:258-269. doi: 10.1016/j.ejmech.2016.02.024. Epub 2016 Feb 9.

PMID:
26900658
13.

Cushing`s disease: Fibrinogen and D-dimer levels fail to normalize despite early postoperative remission - a prospective, controlled study.

Witek P, Zieliński G, Szamotulska K, Witek J, Kamiński G.

Endokrynol Pol. 2016;67(3):283-91. doi: 10.5603/EP.a2016.0034. Epub 2016 Feb 17.

14.

Simeprevir plus sofosbuvir (12 and 8 weeks) in hepatitis C virus genotype 1-infected patients without cirrhosis: OPTIMIST-1, a phase 3, randomized study.

Kwo P, Gitlin N, Nahass R, Bernstein D, Etzkorn K, Rojter S, Schiff E, Davis M, Ruane P, Younes Z, Kalmeijer R, Sinha R, Peeters M, Lenz O, Fevery B, De La Rosa G, Scott J, Witek J.

Hepatology. 2016 Aug;64(2):370-80. doi: 10.1002/hep.28467. Epub 2016 Mar 22.

15.

Simeprevir plus peginterferon/ribavirin for HCV genotype 1-infected treatment-naïve patients in China and South Korea.

Wei L, Han T, Yang D, Heo J, Shang J, Cheng J, Chen X, Xie Q, Kim JH, Kalmeijer R, Ouwerkerk-Mahadevan S, Hoeben E, Lenz O, Verbinnen T, Sinha R, Li M, Scott J, Peeters M, Witek J; TIGER team.

J Gastroenterol Hepatol. 2016 May;31(5):912-20. doi: 10.1111/jgh.13288.

PMID:
26777137
16.

Efficacy of telaprevir-based therapy in stable liver transplant patients with chronic genotype 1 hepatitis C.

Forns X, Samuel D, Mutimer D, Fagiuoli S, Navasa M, Agarwal K, Berenguer M, Colombo M, Herzer K, Nevens F, Daems B, Janssen K, Ouwerkerk-Mahadevan S, Kimko H, Lathouwers E, Witek J, Solingen-Ristea RV.

Ann Hepatol. 2016 Jul - Aug;15(4):512-523. doi: 10.5604/16652681.1202922.

17.

Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: A phase 3 study (OPTIMIST-2).

Lawitz E, Matusow G, DeJesus E, Yoshida EM, Felizarta F, Ghalib R, Godofsky E, Herring RW, Poleynard G, Sheikh A, Tobias H, Kugelmas M, Kalmeijer R, Peeters M, Lenz O, Fevery B, De La Rosa G, Scott J, Sinha R, Witek J.

Hepatology. 2016 Aug;64(2):360-9. doi: 10.1002/hep.28422. Epub 2016 Feb 19.

18.

Telaprevir-based therapy in patients coinfected with chronic hepatitis C virus infection and HIV: INSIGHT study.

Montes ML, Nelson M, Girard PM, Sasadeusz J, Horban A, Grinsztejn B, Zakharova N, Rivero A, Durant J, Ortega-Gonzalez E, Lathouwers E, Janssen K, Ouwerkerk-Mahadevan S, Witek J, González-García J.

J Antimicrob Chemother. 2016 Jan;71(1):244-50. doi: 10.1093/jac/dkv323. Epub 2015 Oct 19.

PMID:
26483516
19.

Ribavirin concentration determines treatment success of first-generation DAA-based chronic HCV therapy.

de Kanter CT, Buti M, DeMasi R, Ouwerkerk-Mahadevan S, Dofferhoff AS, Witek J, Drenth JP, Zeuzem S, Burger DM.

Antivir Ther. 2016;21(2):153-9. doi: 10.3851/IMP2994. Epub 2015 Sep 17.

PMID:
26378941
20.

Ectopic Cushing's syndrome in light of modern diagnostic techniques and treatment options.

Witek P, Witek J, Zieliński G, Podgajny Z, Kamiński G.

Neuro Endocrinol Lett. 2015;36(3):201-8. Review.

PMID:
26313384
21.

Imidazolidine-4-one derivatives in the search for novel chemosensitizers of Staphylococcus aureus MRSA: synthesis, biological evaluation and molecular modeling studies.

Matys A, Podlewska S, Witek K, Witek J, Bojarski AJ, Schabikowski J, Otrębska-Machaj E, Latacz G, Szymańska E, Kieć-Kononowicz K, Molnar J, Amaral L, Handzlik J.

Eur J Med Chem. 2015 Aug 28;101:313-25. doi: 10.1016/j.ejmech.2015.06.013. Epub 2015 Jun 24.

PMID:
26160112
22.

Pharmacokinetics of bound and unbound telaprevir in cirrhotic patients with moderate and severe hepatic impairment.

Ouwerkerk-Mahadevan S, Halabi A, Cieslarová B, Aerts I, Witek J, Van Solingen-Ristea R, Luo D.

J Clin Pharmacol. 2015 Oct;55(10):1147-56. doi: 10.1002/jcph.545. Epub 2015 Jul 7.

PMID:
25975934
23.

Pharmacokinetic interaction between etravirine or rilpivirine and telaprevir in healthy volunteers: A randomized, two-way crossover trial.

Kakuda TN, Leopold L, Nijs S, Vandevoorde A, Crauwels HM, Bertelsen KM, Stevens M, Witek J, van Delft Y, Tomaka F, Hoetelmans RM.

J Clin Pharmacol. 2014 May;54(5):563-73. doi: 10.1002/jcph.245.

PMID:
25975423
24.

Multiple conformational states in retrospective virtual screening - homology models vs. crystal structures: beta-2 adrenergic receptor case study.

Mordalski S, Witek J, Smusz S, Rataj K, Bojarski AJ.

J Cheminform. 2015 Apr 9;7:13. doi: 10.1186/s13321-015-0062-x. eCollection 2015.

25.

Multi-Step Protocol for Automatic Evaluation of Docking Results Based on Machine Learning Methods--A Case Study of Serotonin Receptors 5-HT(6) and 5-HT(7).

Smusz S, Mordalski S, Witek J, Rataj K, Kafel R, Bojarski AJ.

J Chem Inf Model. 2015 Apr 27;55(4):823-32. doi: 10.1021/ci500564b. Epub 2015 Apr 8.

PMID:
25806997
26.

Evolution of hepatitis C virus quasispecies during repeated treatment with the NS3/4A protease inhibitor telaprevir.

Susser S, Flinders M, Reesink HW, Zeuzem S, Lawyer G, Ghys A, Van Eygen V, Witek J, De Meyer S, Sarrazin C.

Antimicrob Agents Chemother. 2015 May;59(5):2746-55. doi: 10.1128/AAC.04911-14. Epub 2015 Feb 23.

27.

An OPTIMIZE study retrospective analysis for management of telaprevir-treated hepatitis C virus (HCV)-infected patients by use of the Abbott RealTime HCV RNA assay.

Sarrazin C, Dierynck I, Cloherty G, Ghys A, Janssen K, Luo D, Witek J, Buti M, Picchio G, De Meyer S.

J Clin Microbiol. 2015 Apr;53(4):1264-9. doi: 10.1128/JCM.03030-14. Epub 2015 Feb 4.

28.

Prevalence of the hepatitis C virus NS3 polymorphism Q80K in genotype 1 patients in the European region.

Sarrazin C, Lathouwers E, Peeters M, Daems B, Buelens A, Witek J, Wyckmans Y, Fevery B, Verbinnen T, Ghys A, Schlag M, Baldini A, De Meyer S, Lenz O.

Antiviral Res. 2015 Apr;116:10-6. doi: 10.1016/j.antiviral.2015.01.003. Epub 2015 Jan 19.

29.

Towards novel 5-HT7versus 5-HT1A receptor ligands among LCAPs with cyclic amino acid amide fragments: design, synthesis, and antidepressant properties. Part II.

Canale V, Kurczab R, Partyka A, Satała G, Witek J, Jastrzębska-Więsek M, Pawłowski M, Bojarski AJ, Wesołowska A, Zajdel P.

Eur J Med Chem. 2015 Mar 6;92:202-11. doi: 10.1016/j.ejmech.2014.12.041. Epub 2014 Dec 24.

PMID:
25555143
30.

Incidence of virological failure and emergence of resistance with twice-daily vs every 8-h administration of telaprevir in the OPTIMIZE study.

Dierynck I, Ghys A, Witek J, Luo D, Janssen K, Daems B, Picchio G, Buti M, De Meyer S.

J Viral Hepat. 2014 Dec;21(12):835-42. doi: 10.1111/jvh.12347.

PMID:
25402544
31.

Telaprevir combination therapy in HCV/HIV co-infected patients (INSIGHT study): sustained virologic response at 12 weeks final analysis.

Montes M, Nelson M, Girard PM, Sasadeusz J, Horban A, Grinsztejn B, Zakharova N, Rivero A, Lathouwers E, Janssen K, Ouwerkerk-Mahadevan S, Witek J.

J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19626. doi: 10.7448/IAS.17.4.19626. eCollection 2014.

32.

Impact of template choice on homology model efficiency in virtual screening.

Rataj K, Witek J, Mordalski S, Kosciolek T, Bojarski AJ.

J Chem Inf Model. 2014 Jun 23;54(6):1661-8. doi: 10.1021/ci500001f. Epub 2014 May 21.

PMID:
24813470
33.

Risk factors predictive of anemia development during telaprevir plus peginterferon/ribavirin therapy in treatment-experienced patients.

Zeuzem S, DeMasi R, Baldini A, Coate B, Luo D, Mrus J, Witek J.

J Hepatol. 2014 Jun;60(6):1112-7. doi: 10.1016/j.jhep.2014.01.013. Epub 2014 Jan 29.

PMID:
24486089
34.

Patterns of viral load decline with telaprevir-based therapy in patients with genotype 1 chronic HCV infection.

Picchio G, De Meyer S, Dierynck I, Ghys A, Gritz L, Kieffer TL, Bartels DJ, Witek J, Bengtsson L, Luo D, Kauffman RS, Adda N, Sarrazin C.

J Clin Virol. 2014 Mar;59(3):148-55. doi: 10.1016/j.jcv.2013.12.011. Epub 2014 Jan 6.

PMID:
24462470
35.

Homeostasis model assessment of insulin resistance does not seem to predict response to telaprevir in chronic hepatitis C in the REALIZE trial.

Younossi Z, Negro F, Serfaty L, Pol S, Diago M, Zeuzem S, Andreone P, Lawitz EJ, Roberts S, Focaccia R, Foster GR, Horban A, Lonjon-Domanec I, Coate B, DeMasi R, Picchio G, Witek J.

Hepatology. 2013 Dec;58(6):1897-906. doi: 10.1002/hep.26437. Epub 2013 Oct 17.

PMID:
24382638
36.

An application of machine learning methods to structural interaction fingerprints--a case study of kinase inhibitors.

Witek J, Smusz S, Rataj K, Mordalski S, Bojarski AJ.

Bioorg Med Chem Lett. 2014 Jan 15;24(2):580-5. doi: 10.1016/j.bmcl.2013.12.017. Epub 2013 Dec 10.

PMID:
24374279
37.

Telaprevir twice daily is noninferior to telaprevir every 8 hours for patients with chronic hepatitis C.

Buti M, Agarwal K, Horsmans Y, Sievert W, Janczewska E, Zeuzem S, Nyberg L, Brown RS Jr, Hézode C, Rizzetto M, Paraná R, De Meyer S, De Masi R, Luo D, Bertelsen K, Witek J.

Gastroenterology. 2014 Mar;146(3):744-753.e3. doi: 10.1053/j.gastro.2013.11.047. Epub 2013 Dec 4.

38.

Pharmacokinetic interaction between telaprevir and methadone.

van Heeswijk R, Verboven P, Vandevoorde A, Vinck P, Snoeys J, Boogaerts G, De Paepe E, Van Solingen-Ristea R, Witek J, Garg V.

Antimicrob Agents Chemother. 2013 May;57(5):2304-9. doi: 10.1128/AAC.02262-12. Epub 2013 Mar 11.

39.

Steady-state pharmacokinetics of etravirine and lopinavir/ritonavir melt extrusion formulation, alone and in combination, in healthy HIV-negative volunteers.

Schöller-Gyüre M, Kakuda TN, Witek J, Akuma SH, De Smedt G, Spittaels K, Vyncke V, Hoetelmans RM.

J Clin Pharmacol. 2013 Feb;53(2):202-10. doi: 10.1177/0091270012445205. Epub 2013 Jan 24.

PMID:
23436265
40.

Pharmacokinetics and short-term safety of etravirine in combination with fluconazole or voriconazole in HIV-negative volunteers.

Kakuda TN, Van Solingen-Ristea R, Aharchi F, Smedt GD, Witek J, Nijs S, Vyncke V, Hoetelmans RM.

J Clin Pharmacol. 2013 Jan;53(1):41-50. doi: 10.1177/0091270011433329. Epub 2013 Jan 24.

PMID:
23400742
41.

Complications of Cushing's disease - prospective evaluation and clinical characteristics. Do they affect the efficacy of surgical treatment?

Witek P, Zieliński G, Szamotulska K, Witek J, Zgliczyński W.

Endokrynol Pol. 2012;63(4):277-85.

42.

[Type 1 diabetes-associated autoimmune diseases: screening, diagnostic principles and management].

Witek PR, Witek J, Pańkowska E.

Med Wieku Rozwoj. 2012 Jan-Mar;16(1):23-34. Review. Polish.

43.

Pooled week 96 results of the phase III DUET-1 and DUET-2 trials of etravirine: further analysis of adverse events and laboratory abnormalities of special interest.

Girard PM, Campbell TB, Grinsztejn B, Hartikainen J, Rachline A, Nijs S, Witek J.

HIV Med. 2012 Aug;13(7):427-35. doi: 10.1111/j.1468-1293.2012.00994.x. Epub 2012 Mar 14.

44.

Pharmacokinetic parameters of once-daily rilpivirine following administration of efavirenz in healthy subjects.

Crauwels H, Vingerhoets J, Ryan R, Witek J, Anderson D.

Antivir Ther. 2012;17(3):439-46. doi: 10.3851/IMP1959. Epub 2011 Nov 9.

PMID:
22293086
45.

[Insulin resistance in children].

Witek J, Witek P, Pańkowska E.

Pediatr Endocrinol Diabetes Metab. 2011;17(4):206-13. Review. Polish.

PMID:
22248781
46.

Efficacy and safety outcomes among treatment-experienced women and men treated with etravirine in gender, race and clinical experience.

Hodder S, Jayaweera D, Mrus J, Ryan R, Witek J; Grace Study Group.

AIDS Res Hum Retroviruses. 2012 Jun;28(6):544-51. doi: 10.1089/AID.2011.0118. Epub 2012 Apr 2.

PMID:
22206504
47.
48.

Ultrafiltrative separation of rhamnolipid from culture medium.

Witek-Krowiak A, Witek J, Gruszczyńska A, Szafran RG, Koźlecki T, Modelski S.

World J Microbiol Biotechnol. 2011 Aug;27(8):1961-1964. Epub 2011 Jan 19.

49.

Short communication prevalence of susceptibility to etravirine by genotype and phenotype in samples received for routine HIV type 1 resistance testing in the United States.

Picchio G, Vingerhoets J, Tambuyzer L, Coakley E, Haddad M, Witek J.

AIDS Res Hum Retroviruses. 2011 Dec;27(12):1271-5. doi: 10.1089/aid.2011.0049. Epub 2011 Jun 11.

PMID:
21557669
50.

Safety and pharmacokinetics of etravirine in pregnant HIV-1-infected women.

Izurieta P, Kakuda TN, Feys C, Witek J.

HIV Med. 2011 Apr;12(4):257-8. doi: 10.1111/j.1468-1293.2010.00874.x. No abstract available.

Supplemental Content

Support Center